Gentronix Raises £700K In Funding

The latest round, which includes a number of private investors, follows Gentronix’s recent acquisition of the Big Blue® transgenic mutation assay from Merck KGaA. It will be used to fund the onboarding and delivery of the new service and expand its genetic, skin and ocular toxicology services.
（以上内容由医药魔方AI生成）